

Gujranwala Liver Foundation [GLF] was established by a group of philanthropists in 2007 with the following aims;
The Clinic:
At present the activities of the foundation include a daily hepatology clinic. Any patient who suffers from liver disease is eligible for registration in the GLF clinic. To date there are nearly 13000 registered patients and approximately 90% of these are hepatitis C virus positive. These patients are provided expert opinion, specialized investigations and the best possible treatment as per national and international treatment guidelines.
At GLF, we follow a model of subsidy and facility. The investigations and treatment is made available to the patients at subsidized rates. Complete funding of treatment is offered to those who are deemed to deserve by our board according to a well-established criteria. Average monthly income of the patients visiting GLF is less than Rs. 9000.
The clinic is managed by a team of Hepatologist, dedicated medical officers and trained staff. Since November 2012, our endoscopy unit is also functional. This facility is being offered at nominal cost to the poor patients without any compromise on standards.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close